|
Iniesta P, Revilla N, Chen-Liang TH, Hurtado AM, Vicente V, Heras I, Jerez A, Lozano ML. An early increase of CD56(bright) natural killer subset as dominant effect and predictor of response to extracorporeal photopheresis for graft-versus-host disease. Transfusion. 2018 Dec;58(12):2924-2932. doi: 10.1111/trf.14964. Epub 2018 Sep 27. PubMed PMID: 30260547.
AÑO: 2018; IF: 3.111
|
|
Martínez-Laperche C, Buces E, Aguilera-Morillo MC, Picornell A, González-Rivera M, Lillo R, Santos N, Martín-Antonio B, Guillem V, Nieto JB, González M, de la Cámara R, Brunet S, Jiménez-Velasco A, Espigado I, Vallejo C, Sampol A, Bellón JM, Serrano D, Kwon M, Gayoso J, Balsalobre P, Urbano-Izpizua Á, Solano C, Gallardo D, Díez-Martín JL, Romo J, Buño I; GVHD/Immunotherapy Committee of the Spanish Group for Hematopoietic Transplantation. A novel predictive approach for GVHD after allogeneic SCT based on clinical variables and cytokine gene polymorphisms. Blood Adv. 2018 Jul 24;2(14):1719-1737. doi: 10.1182/bloodadvances.2017011502. PubMed PMID: 30030270; PubMed Central PMCID: PMC6058238.
AÑO: 2018; IF: 4.584
|
|
Cabrero M, Martin A, Briones J, Gayoso J, Jarque I, López J, Grande C, Heras I, Arranz R, Bernal T, Perez-Lopez E, López-Godino O, Conde E, Caballero D. Phase II Study of Yttrium-90-Ibritumomab Tiuxetan as Part of Reduced-Intensity Conditioning (with Melphalan, Fludarabine ± Thiotepa) for Allogeneic Transplantation in Relapsed or Refractory Aggressive B Cell Lymphoma: A GELTAMO Trial. Biol Blood Marrow Transplant. 2017 Jan;23(1):53-59. doi: 10.1016/j.bbmt.2016.10.003. Epub 2016 Oct 19. PubMed PMID: 27771496.
AÑO: 2017; IF: 4.484
|
|
Kwon M, Bautista G, Balsalobre P, Sánchez-Ortega I, Montesinos P, Bermúdez A, de Laiglesia A, Herrera P, Martin C, Humala K, Zabalza A, Torres M, Bento L, Corral LL, Heras I, Serrano D, Buño I, Anguita J, Regidor C, Duarte R, Cabrera R, Gayoso J, Diez-Martin JL. Haplo-Cord transplantation compared to haploidentical transplantation with post-transplant cyclophosphamide in patients with AML. Bone Marrow Transplant. 2017 Aug;52(8):1138-1143. doi: 10.1038/bmt.2017.36. Epub 2017 Mar 27. PubMed PMID: 28346415.
AÑO: 2017; IF: 4.497
|
|
Gayoso J, Balsalobre P, Pascual MJ, Castilla-Llorente C, López-Corral L, Kwon M, Serrano D, Piñana JL, Herrera P, Ferrá C, Pascual C, Heras I, Montesinos P, Zabalza A, Bento L, Figuera A, Buño I, Díez-Martín JL. Busulfan-based reduced intensity conditioning regimens for haploidentical transplantation in relapsed/refractory Hodgkin lymphoma: Spanish multicenter experience. Bone Marrow Transplant. 2016 Oct;51(10):1307-1312. doi: 10.1038/bmt.2016.115. Epub 2016 May 9. PubMed PMID: 27159177.
AÑO: 2016; IF: 3.874
|
30260547